Home › Blood Disorders
Blood Disorders clinical trials recruiting in the U.S.
34 studies for Blood Disorders are recruiting participants at sites across the United States.
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
Cities with the most studies
- Boston, MA10 studies
- Atlanta, GA10 studies
- Houston, TX9 studies
- Los Angeles, CA9 studies
- The Bronx, NY8 studies
- New York City, NY7 studies
- Nashville, TN7 studies
- Mountain View, CA6 studies
- Durham, NC5 studies
- Washington, DC5 studies
- Greenville, NC5 studies
- Portland, OR5 studies
- Seattle, WA5 studies
- Birmingham, AL4 studies
- Milwaukee, WI4 studies
- San Diego, CA4 studies
- Philadelphia, PA4 studies
- Tampa, FL4 studies
- Baltimore, MD3 studies
- Baldwin Park, CA3 studies
- Buffalo, NY3 studies
- Columbus, OH3 studies
- Cleveland, OH3 studies
- Norfolk, VA3 studies
- Louisville, KY3 studies
- Indianapolis, IN3 studies
- Kansas City, MO3 studies
- Cedar Rapids, IA3 studies
- Miami, FL3 studies
- Phoenix, AZ3 studies
- Clifton, NJ3 studies
By state
- Alabama5 studies
- Arizona3 studies
- Arkansas3 studies
- California16 studies
- District of Columbia4 studies
- Florida9 studies
- Georgia11 studies
- Indiana3 studies
- Iowa3 studies
- Kentucky4 studies
- Maryland5 studies
- Massachusetts10 studies
- Minnesota3 studies
- Missouri4 studies
- New Jersey5 studies
- New York12 studies
- North Carolina9 studies
- Ohio6 studies
- Oregon5 studies
- Pennsylvania4 studies
- Tennessee7 studies
- Texas10 studies
- Virginia5 studies
- Washington6 studies
- Wisconsin5 studies
Recently updated studies
Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
RecruitingPhase 1
3 Months – 25 Years · All sexes · Updated Oct 2, 2026 · NCT04806347A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 28, 2026 · NCT06439082Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Recruiting
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06910969Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458Treatment of Hemophilia A Patients With FVIII Inhibitors
RecruitingObservational study
All ages · Men · Updated Sep 23, 2026 · NCT04023019A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 11, 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07601425A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07075185A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Recruiting
Up to age 55 · All sexes · Updated Jul 6, 2026 · NCT01666080Therapeutic RSK1 Targeting in Myelofibrosis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07379125A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317ATHNdataset Registry
RecruitingObservational study
All ages · All sexes · Updated Apr 21, 2026 · NCT06820515Diamond Blackfan Anemia Registry (DBAR)
RecruitingObservational study
All ages · All sexes · Updated Apr 16, 2026 · NCT00106015Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Apr 16, 2026 · NCT06828796Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
RecruitingObservational studyHealthy volunteers welcome
Ages 19 and older · All sexes · Updated Apr 2, 2026 · NCT03207854Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RecruitingPhase 3
Ages 12 to 35 · All sexes · Updated Mar 23, 2026 · NCT05477563Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
RecruitingPhase 1
1 Month – 45 Years · All sexes · Updated Jan 8, 2026 · NCT04640987Hematology Biobank: In Vitro Study of Blood Disorders
RecruitingObservational study
Ages 12 and older · All sexes · Updated Jan 6, 2026 · NCT02442011CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
RecruitingPhase 1
3 Months – 30 Years · All sexes · Updated Nov 28, 2025 · NCT06559189From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.